Basimglurant

Basimglurant (INN) (code names RG-7090, RO4917523) is a negative allosteric modulator of the mGlu₅ receptor which is under development by Roche for the treatment of treatment-resistant depression (as an adjunct) and fragile X syndrome. As of August 2014, it is in phase II clinical trials for both of these indications.